



Keywords: Ventricular assist; Anticoagulation; INTERMACS; Heartware

Introduction

Left ventricular assist devices have significantly changed the way physicians manage advanced heart failure. Ventricular Assist Device (Heartware Inc., Framingham, MA) was placed a month after the initial STEMI, without cardiopulmonary bypass. An echo was performed the following day which showed no systolic opening of the aortic valve at 2300-2500 revolutions per minute and minimal opening of the aortic valve at 2200 revolutions per minute. The IABP was removed on post-operative day 1 and he was extubated on post-operative day 4. The milrinone was weaned off and he was discharged home on post-operative day 18 on amiodarone 200 mg daily, furosemide 20 mg daily, losartan 25 mg daily, spironolactone 25 mg daily, and warfarin 4 mg daily.

During the first day he had an episode of bradycardia; dobutamine was started at 2.5 mcg/kg/min and increased to 5 mcg/kg/min. The dobutamine was eventually stopped and the IABP was removed. He went into cardiogenic shock and the IABP was replaced within 12 h and he was started on norepinephrine and milrinone at 0.25 mcg/kg/h.

The norepinephrine was weaned off; however, the milrinone and IABP were unable to be discontinued. He was in cardiogenic shock with a New York Heart Association (NYHA) Class IV heart failure with a reduced ejection fraction with a life expectancy of less than 6 months and his Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile 2. A repeat echo showed an ejection fraction of 20% and regional wall abnormalities in the left anterior descending and right coronary artery territories. In addition, he had intermittent arrhythmias, including supraventricular tachycardia and

atrial fibrillation with rapid ventricular rate. The patient needed a left ventricular assist device in order to improve and be discharged.

The patient was taken to the operating room and a Heartware left ventricular assist device (Heartware Inc., Framingham, MA) was placed a month after the initial STEMI, without cardiopulmonary bypass. An echo was performed the following day which showed no systolic opening of the aortic valve at 2300-2500 revolutions per minute and minimal opening of the aortic valve at 2200 revolutions per minute. The IABP was removed on post-operative day 1 and he was extubated on post-operative day 4. The milrinone was weaned off and he was discharged home on post-operative day 18 on amiodarone 200 mg daily, furosemide 20 mg daily, losartan 25 mg daily, spironolactone 25 mg daily, and warfarin 4 mg daily.

The patient presented to an outside hospital with complaints of his ventricular assist device alarming 13 days after discharge. The International Normalized Ratio (INR) was sub-therapeutic at 1.2 and the Lactate Dehydrogenase (LDH) level was greater than 1000 Units/L. He was started on therapeutic enoxaparin at 90 mg every 12 h and transferred to our institution. There was concern for an acute LVAD thrombosis. The power on the LVAD was 15 Watts, the flow was >10 L, and the pump speed was 2,400 RPMs. A transthoracic echo showed an ejection fraction of 40-45% with mild left ventricular dilation. A cardiac catheterization was performed.

*Corresponding author: Hannah Copeland, McGuire VA Medical Center, Virginia Commonwealth University, Surgical Service (112), 1201 Broad Rock Blvd, Richmond, VA 23249, USA, Tel: 804-675-5403; Fax: 804-675-5402; E-mail: hannahcopeland411@gmail.com

Received

leaving the ventricular assist device in place is an option.

Citation: Saleem K, Copeland H, Hadi A, Wang I, Wozniak TC, et al. (2017) Ligation of the Outflow Tract for the Treatment of Pump Thrombosis of a Left Ventricular Assist Device. *J Clin Exp Transplant* 2: 114.

kg/min. During this time, he was given another bolus of eptibatide at 180 mcg/kg and then a continuous infusion at 2 mcg/kg/min for an additional 48 h. The LVAD flow continued to remain at 10 L with
